Latest News Archive

Please select Category, Year, and then Month to display items

Internationalisation at home: Perspectives from abroad

30 April 2020 | Story Baptiste Becret | Photo Supplied

Since the approval of the University of the Free State (UFS) internationalisation strategy for 2018-2022, the UFS community and staff members of the Office for International Affairs (OIA) have been working hard to try and realise the goals stated in the strategy. The policy states “the university's’ commitment to developing curricula that are locally relevant, globally competitive and connect to multiple knowledge paradigms”. Furthermore, “We expect that the new internationalisation strategy will advance the international positioning of the university, and synergise the existing rich international activities into intentional, comprehensive internationalisation processes”.

In an effort to realise the said expectations through the university’s inbound mobility programme, the Department of Afrikaans and Dutch, German and French in the Faculty of the Humanities has hired Baptiste Becret, an exchange student from French partner university, Science PO Bordeaux, as French tutor for the first semester of 2020. This collaboration by the two departments endeavours to achieve the university’s vision of developing its students’ international and intercultural competencies through internationalisation at home. Equally, this initiative speaks to a critical aspect of internationalisation, the “purposeful integration of international and intercultural dimensions into the formal curriculum for the UFS students within the domestic learning environment”.

Being the only Frenchman on campus

“I was the only Frenchman on campus and at the university, which I rather enjoyed. I learned at the beginning of this year, in January, that I could share my culture and language by helping students participating in the first- and second-year French courses at the university. For my part, I was attached to the Faculty of the Humanities. I've already had experience as a tutor in France, so I wasn't very stressed at the idea of being in front of a class. I enjoyed trying to teach my mother tongue. My contact with the French teacher was good. He gave me a lot of freedom to do the activities I wanted to do.

I didn't think that passing on my knowledge to the first-year class would be so difficult. Indeed, for some of them, they have never spoken a word of French. But the atmosphere improved from class to class after a shy start. I hope I was able to help them as best I could. In any case, I was very happy to teach them and to assist them in their various difficulties with the language. For the second-year class, the atmosphere was a little different. The class was smaller, the students already knew each other well, and they were pretty close. Additionally, their language level was already good.

All this to say that being a French tutor was a great experience. It was enriching for both parties (students and me). Of course, I tried to do the best I could, and I took advantage of the free time my schedule gave me to share a little bit of my home country. So, I advise future international students – if they feel comfortable with that – to give it a try. It's only two hours a week with a little bit of extra money. Finally, I would like to thank the International Office for informing me of this opportunity, the people involved in the programme, including my coordinator, the French teacher, and especially the students who have been super cool to me.”

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease

2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013

The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.

In future further evaluation will be performed in other forms of hypocholesterolemia.

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.

Back

Economic and Management Sciences

Education

Health Sciences

The Humanities

Law

Natural and Agricultural Sciences

Theology and Religion

Open Distance Learning

Business School

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept